End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
59.11 CNY | -0.94% | +18.86% | +7.53% |
04-25 | Hangzhou Tigermed Consulting’s Profit Down 59% in Q1 | MT |
04-25 | Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With a 2024 P/E ratio at 29.35 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.53% | 6.6B | B+ | ||
+0.17% | 42.19B | B | ||
+44.30% | 40.15B | A | ||
-6.20% | 28.31B | C | ||
+5.23% | 24.63B | B- | ||
-24.79% | 18.2B | B | ||
+26.69% | 12.01B | C+ | ||
-3.13% | 11.76B | C+ | ||
+6.57% | 10.4B | B+ | ||
-18.08% | 9.94B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300347 Stock
- Ratings Hangzhou Tigermed Consulting Co., Ltd